MoneyWorks4Me

Beryl Drugs - Quaterly Results

13 Feb 2023 Evaluate
The Total revenue for the quarter ended December 2022 of  Rs. 81.90 millions grew by 154.43% from Rs. 32.19 millions.The Total Profit for the quarter ended December 2022 of Rs. 1.43 millions grew from Rs.-1.02 millionsOP of the company witnessed a marginal growth to 7.15 millions from 2.45 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 81.90 32.19 154.43 210.63 112.48 87.26 147.69 142.80 3.42
Other Income 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBIDT 7.15 2.45 191.84 19.40 8.61 125.32 5.73 16.36 -64.98
Interest 1.17 1.15 1.74 3.55 3.37 5.34 4.37 4.66 -6.22
PBDT 5.98 1.30 360.00 15.85 5.24 202.48 1.36 16.22 -91.62
Depreciation 2.20 2.72 -19.12 6.61 8.16 -19.00 10.86 12.73 -14.69
PBT 3.78 -1.42 -366.20 9.24 -2.92 -416.44 -9.50 3.49 -372.21
TAX 2.35 -0.40 -687.50 2.21 -1.07 -306.54 -2.91 1.08 -369.44
Deferred Tax 2.35 -0.40 -687.50 2.21 -1.07 -306.54 -3.00 1.08 -377.78
PAT 1.43 -1.02 -240.20 7.03 -1.85 -480.00 -6.59 2.41 -373.44
Equity 50.72 50.72 0.00 50.72 50.72 0.00 50.72 50.72 0.00
PBIDTM(%) 8.73 7.61 14.70 9.21 7.65 20.32 3.88 11.46 -66.13
Peers
Company Name CMP
Sun Pharma. Inds. 1847.00
Dr. Reddys Labs. 1212.30
Cipla 1368.65
Lupin 2121.05
Zydus Lifesciences 1170.00
View more..